Alnylam Hopes For Strong hATTR Uptake For Vutrisiran With Longer Data

 
• By Alaric DeArment

The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.

High quality 3d render of nerve cells, concept for Neurologic Diseases, tumors and brain surgery.
Alnylam presented 18-month data from the HELIOS-A study of vutrisiran in hATTR amyloidosis with polyneuropathy • Source: Shutterstock

Alnylam Pharmaceuticals Inc. anticipates its drug vutrisiran will take a bigger chunk of the market for hereditary transthyretin-mediated (hATTR) amyloidosis after presenting long-term data in patients with polyneuropathy. The new 18-month data should also fulfill the requirements for the company to file for European Medicines Agency approval, whereas the drug is already under US Food and Drug Administration review based on 9-month data.

On 21 January, Alnylam presented 18-month data from the Phase III HELIOS-A study of vutrisiran at the Société Francophone du...

More from Archive

More from Scrip

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By Andy Smith

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.

Lilly’s Muscle Builder Looks Strong In GLP-1 Obesity Combo

 
• By Andrew McConaghie

Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.